The GBA Group has acquired a majority stake in Johner Institut GmbH, further expanding its position as a leading European platform for medical device services. With the internationally recognized expertise and excellent reputation of the Johner Institute, the GBA Group significantly strengthens its regulatory and technological capabilities in the medical device sector and expands its service portfolio, particularly in consulting and training. The acquisition represents the next logical step in the GBA Group’s strategy to further strengthen its market position in the life sciences sector.

EcoVadis evaluates companies based on key areas such as the environment, labour and human rights, ethics, and sustainable procurement. Maintaining our Silver status while raising our score demonstrates our ongoing commitment to responsible and sustainable business practices.

For almost three years now, we have been offering our leaders a workshop program specifically geared towards their practical need. It covers leadership topics, legal issues, HR, process management, and business basics. We celebrate the end of the program at a joint event discussing about leadership with representatives of our C-level management and exchanging ideas.

GBA Group and Eureka Analytical Services Pvt Ltd intensify their partnership to strengthen and sharpen their position in the global market.

Today, GBA Group announces that Eureka Analytical Services Pvt Ltd (Eureka) is now an official member of GBA Group. GBA Group’s entry into the Indian market is a key element of its growth strategy, as India's rapid, dynamic and future-oriented development as an international business hub, as well as its geographical location, offers great potential for growth in various business areas.

GBA Group is expanding its range of toxicology services for customers in the chemical, medical device and pharmaceutical industries with the acquisition of ICCR-Roßdorf GmbH (ICCR-Roßdorf). This acquisition underlines GBA Group's ambition to position itself broadly as an international life science service provider through targeted portfolio expansions and investment in leading CROs.